About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot

Physical activity & checkpoint inhibition: association with toxicity & survival JNCI doi.org/10.1093/jnci/d… 🇩🇰 RWD, 251 pts Higher physical activity levels at the start of ICI treatment: 👉 lower risk of severe irAEs 👉 probably longer survival 😅"easy" to implement

#AACR24 Opening plenary Eye-opening talk on use of digital pathology/AI & it’s ability to optimize cancer care by Jakob Nikolas Kather, through: - prediction of MSI-status on H+E digital path - tx selection (e.g. atezo-bev in HCC) - integrated models with language AACR OncoAlert #LCSM

#AACR24 Biomarker session Analysis of biomarkers of response for neoadj pembro+ramucirumab in resectable NSCLC in EAST-ENERGY trial, shows: - pre-Tx high CD8 T cells seen in those with MPR - Tregs/CD8 ratio & M2 macrophages not assoc with outcome AACR OncoAlert #LCSM

Just published! #Metabolic Signaling in Cancer #Metastasis, a #CancerHallmarks review, by #AACR24 Plenary Speaker and winner of the AACR Award for Outstanding Achievement in Basic Cancer Research, Sarah-Maria Fendt (@FendtLab). bit.ly/4cOSzp2 @VIB KU Leuven

#lungcancer is the #1 cause of #cancer related deaths worldwide 🌏. ➡️ But did you know that #Lungcancer in Never Smokers (LCINS) is the 5th most common cause of #cancer related deaths 🌏? Fantastic talk by Elaine Shum from NYU Langone Health today at #AACR24. AACR OncoAlert

Headed back to east coast after an outstanding AACR #AACR24 meeting in San Diego.

RMC-6236 achieved the impossible. A COMPLETE RESPONSE in a heavily pretreated PDAC patient w liver and peritoneal mets Cancer Discovery Excited lab members Grace Goodhart Amber Amparo could contribute to the nature papers leading up to this KenOliveLab Syed A. Ahmad KRASKickers

Are ICIs safe in pts with solid organ transplant? Multicentre retrospective study Jordi Remon ESMO Open: - 31pts (98% kidney, 36% NSCLC) - irAEs➡️ICI stop 12.9% - rejection rate 25.8% (mono 28% combo 33% p NS) A privilege to review this paper OncoAlert sciencedirect.com/science/articl…

Ph III IMscin001 trial of Subcutaneous (sc) vs IV Atezolizumab in adv NSCLC JTO & JTO CRR: - mOS 10.7 v 10.1m - median admin time sc: 7mins - similar toxicity A step forward in implementing anti-PD(L)1 across growing nos. of indications? OncoAlert #LCSM jto.org/article/S1556-…

Have u ever seen curves as wide as this for any drug recently? Lorlatinib for metastatic ALK positive NSCLC. Great results 👏. It works With reduced dose also. Let's hope it becomes more accessible. @asco #asco24 OncoAlert Oncology Brothers LARVOL Alfredo Addeo MD H. Jack West, MD, FASCO

‼️ Ivonescimab (PD-1/VEGF) + chemo post Osimertinib ✅ ⬆️ PFS ❓ ⬆️ OS benefit (immature) ✅ ⬆️ ORR ✅ ⬆️ DoR ✅ Minor additional tox vs. chemo 🤔 Impressive PFS benefit: same as MARIPOSA-2 🤔 None of Amivantamab toxicity issues 🤔 Big challenge to Ami 🤜🤜 #ASCO24 #LCSM

100 AI Tools to replace your tedious work: 1. Research - ChatGPT - YouChat - Abacus - Perplexity - Copilot - Gemini 2. Image - Fotor - Stability AI - Midjourney - Microsoft Designer 3. CopyWriting - Rytr - Copy AI - Writesonic - Adcreative AI 4. Writing - Jasper - HIX AI

It's been 8 long hours since Bangladesh, a country of 170 million, has been out of communication with the rest of the world. The authorities in Bangladesh shut down the cellular network and internet service across the entire country following violent clashes between security

#StarLinkforBangaldesh Starlink CNN International

Evidence from omics that aging is not a gradual, linear process. The new study, highlighted here, only assessed people up to age 75 among 108 participants with short term follow-up (1.7 yrs). A previous large study (N>4,200, up to age 95) found a 3rd peak at age 80.

Frequency of HER2 alterations across tumor types & current development landscape of HER2-targeted therapies summarized in this publication. nature.com/articles/s4157…

#WCLC24 Presidential I Ph III HARMONI-2 ivonescimab v pembro in PDL>1% NSCLC: - 398pts - PFS HR 0.51 (11.1 v 5.82 mPFS) - benefit across histology & PDL1 🌟 Impressive data overall ❓Is this a step forward for PDL1 1-49% grp? 80% males enrolled, data needed in women IASLC

#Amivantamab + Chemo now U.S. FDA approved in 2L mEGFR NSCLC after Osimertinib based off #MARIPOSA2: - mOS 17.7mos w/ Ami vs 15.3mos with chemo alone (HR 0.73), but ‘did NOT reach pre-specified significance’ - mPFS2 16mos vs 11.6mos (HR: 0.64) #ESMO24 #OncTwitter #lcsm

Immune system one pager